Abstract 175P
Background
Helicobacter pylori-induced aberrant JAK/STAT3 signaling contributed to the development of gastric cancer. We hypothesize that activated STAT3 may epigenetically repress it’s targets by DNA methylation. The object of this study is to identified the diagnostic and prognostic value of novel STAT3 targets that are hypermethylated in gastric cancer.
Methods
Fifty patients’ clinical data and genomic DNA were collected from the Changhua Christian Hospital, Taiwan. DNA methylation microarray was used to analyze the methylation status in AGS gastric cancer cells and patient samples with different STAT3 status. Bioinformatic analyses was carried out to identify STAT3 targets with differential methylation status. Bisulphite pyrosequencing was designed and performed in cancer and normal tissue to examine the methylation level of the target genes. Receiver operating character (ROC) curve and the survival analysis were examined.
Results
We found that promoter hypomethylation of PCDHB15, a potential STAT3 target, was observed in AGS cells depleted with STAT3, while promoter hypermethylation was observed in patient samples with activated STAT3. Cell line studies found that treatment with the DNMT inhibitor, 5azaDC, restored PCDHB15 expression in AGS. Pyrosequencing in various cell lines, including AGS, MKN28, MKN45, SNU1 and SNU16, demonstrated hypermethylation of the PCDHB15 promoter. Compared to the cancer tissue, a lower PCDHB15 methylation was observed in matched adjacent tissue (P = 0.001) and gastritis tissue (P < 0.001). Interestingly, Kaplain-Meier analysis found that patients with higher PCDHB15 methylation had longer survival as compared to patients with lower methylation (p = 0.03).
Conclusions
Our study indicate that methylated PCDHB15 promoter may be associated with development of gastric cancer. Patients with higher PCDHB15 methylation are prone to have better prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This study was supported by a grant from Taichung Veterans General Hospital (RVHYCY-107008).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
154P - Genetic characteristics of participants in the Australian Pancreatic Screening Study
Presenter: Krithika Murali
Session: Poster display session
Resources:
Abstract
155P - Mean Platelet Volume (MPV) is it a new prognostic marker in resectable carcinoma stomach?
Presenter: Girish M. S
Session: Poster display session
Resources:
Abstract
156P - A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis
Presenter: Zhen Xiang
Session: Poster display session
Resources:
Abstract
157P - Lymph node ratio (LNR) a better prognostic factor after D2 gastrectomy
Presenter: Jitin Yadav
Session: Poster display session
Resources:
Abstract
158P - A clinical significance of preoperative C-reactive protein/albumin ratio in patients with extrahepatic bile duct cancer
Presenter: Kim Jinkook
Session: Poster display session
Resources:
Abstract
159P - The relation between obesity and cancer of gastrointestinal tract in Korea: The data from Statistic Korea between 2001 and 2016
Presenter: Hee Man Kim
Session: Poster display session
Resources:
Abstract
160P - Clinical outcomes of second-line chemotherapy after progression on nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma
Presenter: Jooyoung Ha
Session: Poster display session
Resources:
Abstract
161P - Chitinase 3-Like 1 gene (T/C) polymorphism and serum YKL-40 in hepatocellular carcinoma
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
162P - Hypofractionated radiotherapy for pulmonary metastases from hepatocellular carcinoma: Treatment response and prognostic factors affecting survival
Presenter: In Young Jo
Session: Poster display session
Resources:
Abstract
163P - Excision repair cross-complementation group 1 and 2 (ERCC1/2) Single nucleotide polymorphisms and chemotherapy treatment outcome in Cholangiocarcinoma
Presenter: Thanachai Sanlung
Session: Poster display session
Resources:
Abstract